



































The Trp73 gene belongs to the p53 family of 
transcription factors and, like the other members, is 
transcribed into different isoforms [1-4]. TP73 gene 
contains two promoters, encoding the transcriptional 
domain-containing (TAp73) and the amino deleted 
(ΔNp73) isoforms [5, 6]. Furthermore alternative 
splicing at the 3’-end (to generate α, β, γ, etc isoforms) 
and 5’-end (to generate Δ2,  Δ3 and Δ2-3 isoforms) 
results in generation of at least 14 different transcripts, 
with different abilities to promote or repress apoptosis 
[7, 8]. DNA damaging agents induce TAp73 and 
activate p73-dependent gene expression program to 
promote cell cycle arrest and apoptosis. Interestingly, 
ΔNp73 can counteract these activities, either by directly 
binding and inhibiting transcription or by competing for 
DNA binding sites [9-13]. This suggests that the overall 
activity of p73 stems from the relative expression level 
of each isoform, rather  than the  independent  activities  
 
 


































of single isoforms. The relative expression level is 
maintained both at transcriptional level and post-
translational level. While p73 levels are regulated via 
acetylation, phosphorylation, interaction with PML, 
caspase cleavage and degradation by the ubiquitin 
ligase ITCH [14-19], ΔNp73 isoforms are selectively 
degraded by the E3 ubiquitin ligase PIR2 or via the 
antizyme pathway [20, 21]. Although experimental 
evidence and epidemiological studies point to a role of 
p73 in cancer[22-24], clear, unbiased data are only very 
recent [25, 26]. Direct mutations of p73 in tumours are 
rare, but several studies have revealed a clear tendency 
towards upregulation of ΔNp73 isoforms and 
methylation dependent silencing of TAp73, resulting in 
an imbalance of TA/ΔN ratio. Furthermore, recently 
developed isoform specific knockout mice have shown 
that depletion of TAp73 predisposes to cancer, while 
absence of  ΔNp73 impairs tumour  growth in transplant  
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investigate the expression of p73 N-terminal isoforms 
in a panel of cell lines and mouse tissues. First, we 
used N-terminal selective primers to analyse the 
expression of TAp73 and ΔNp73 by qPCR in several 
cancer cell lines (Figure 1A). Surprisingly, we found 
consistently higher expression of TAp73 isoforms in 
the selected cell lines, with the exception of the T-cell 
leukemia Jurkat cells, where TAp73 and ΔNp73 
wereequally expressed. It is noteworthy that in some 
cell lines like MCF7, COS7 and SW480 we found an 
impressive imbalance between the two isoforms with 
up to 100 fold higher TAp73 levels. Next, to validate 
qPCR data, we investigated protein expression in some 
of the previous cell lines. To this aim, we used a 
previously described pan-p73 antibody [27] and 
utilized p73 siRNA and overexpression of p73 
isoforms as controls. Importantly, protein expression 
levels paralleled mRNA data. Indeed, TAp73α was the 
most abundant endogenous isoform detected in cells. 
As shown in Fig 1B/C/D, in most of the cell lines, we 
detected a 75kDa band that co-migrated with TAp73α 
positive control and was efficiently silenced by 
siRNA. Moreover, etoposide treatment in H1299 cell 
line led to the up-regulation of the 75kDa band 
(Figure1C), further substantiating efficient detection of 
TAp73 by the aforementioned antibody. In addition, 
we analysed p73 N-terminal isoforms expression in 
mouse tissues. Interestingly, analysis of TA/ΔN ratio, 
confirmed higher TAp73 expression in-vivo in many 
organs (Figure 1E). In fact, higher relative levels (>10 
fold) of TAp73 mRNA were found in spleen, fat, 
kidney and bladder, while intermediate levels (<10 
fold) were detected in liver, lung and gut. On the other 
hand, ΔNp73 was the main isoform detected in uterus, 
salivary gland and tongue. Finally, comparable levels 
of TA and ΔNp73 mRNAs were expressed in skin, 
brain, colon and ovary. In summary, we carried out an 
extensive study of p73 N-terminal isoforms expression 
both in human cancer cell lines and mouse tissues. 
Surprisingly, our data showed that transcriptionally 
competent TA isoforms were detectable at higher 
levels in most of the cell lines and tissues that were 
analysed. This is counterintuitive considering the 
current knowledge on p73, especially in cancer 
samples, as one would expect increased ΔNp73 
expression to be a hallmark of cancer. Also this raises 
the question about the role of TAp73 in these cells and 
how its anti-proliferative functions are dealt with. 
Finally, data on N-terminal p73 isoform expression in 
primary tumours would be highly beneficial, as this 
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